Peter Ellmark

[Peter Ellmark @EllmarkPeter]

Happy to share new paper highlighting mitazalimabs role in degrading storms and enhancing T cell infiltration in PDAC tumors.

https://t.co/mnsgDpFcOJ

https://t.co/uz8JipLnWk

[Peter Ellmark @EllmarkPeter]

Mitazalimab plus mFOLFIRINOX in Metastatic Pancreatic Cancer: Insights from the OPTIMIZE-1 Study https://t.co/47Wj2d7f6r

[Peter Ellmark @EllmarkPeter]

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic panc... https://t.co/mD5RZecOmz

[Peter Ellmark @EllmarkPeter]

Happy to share our new article!

ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell–dependent tumor immunity and synergizes with PD-1 blockade https://t.co/tNPb5aJoBS

Thanks to all co-authors!

[Peter Ellmark @EllmarkPeter]

First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies https://t.co/ZL1QBfQbJG

[Journal for ImmunoTherapy of Cancer @jitcancer]

In honor of #InternationalWomensDay, we recognize the following remarkable women who lead important #JITC sections as editors. Thank you! 👏
Dr. Sandra Demaria @WeillCornell
Dr. @MarcelaMaus (MassGen)
Dr. Claudia Palena @theNCI
Dr. Alexandra Snyder @generate_biomed

[Peter Ellmark @EllmarkPeter]

Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate – Alligator Bioscience https://t.co/HRijdQlJMR

[Journal for ImmunoTherapy of Cancer @jitcancer]

Congratulations to #JITC Section Editor Dr. Cornelis "Kees" Melief of @UniLeidenNews for being recognized as this year's Pedro J. Romero Service to JITC Award recipient! Thank you for all of your leadership and for sharing your vision with the journal!

[Bernard A Fox @BernardAFox]

Prof. Leisha A. Emens MD PHD, incoming President of SITC “The Society is working to put itself out of business” curing #cancer/new VP, Dr James L. Gulley MD PHD - SITC “Family, Friends, Country” THE SOCIETY IS IN GREAT HANDS! @gulleyj1 @theNCI @FDAOncology @sitcancer #SITC2022

[Journal for ImmunoTherapy of Cancer @jitcancer]

Congratulations to this year's #JITC Best Paper Award recipients - the first authors of top original research papers from the past year! Read the papers using the QR codes and hear more about them during Session 207 in hall 205ABC! #SITC22 @McAuliffe_James @ShrutiGkidney

[Bernard A Fox @BernardAFox]

The Steven A. Rosenberg Scholar Award Recipient is Dr. @emilykeungMD @MDAndersonNews @JenWargoMD !! #SITC2022 #SITC22 @sitcancer

[Journal for ImmunoTherapy of Cancer @jitcancer]

#SITC22 Attendees: Meet #JITC Editor-in-Chief Pedro Romero and Deputy Editor-in-Chief James L Gulley today at 12:30pm EST at the SITC booth. Bring your questions!

[Peter Ellmark @EllmarkPeter]

Very proud to be part of the Alligator team behind this manuscript describing how our Neo-X-Prime technology delivers next generation CD40 targeting therapies

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies https://t.co/4280sOaGUL @EllmarkPeter

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies https://t.co/4280sOaGUL @EllmarkPeter

[Alligator Bioscience @AlligatorBio]

Alligator Bioscience starts clinical phase I study with ATOR-1015 https://t.co/hgl76KKDKe

[Alligator Bioscience @AlligatorBio]

Scrip interviewed CEO Per Norlén last week at BIO-Europe on the company's business development strategies and development triggers. https://t.co/WY3Xf4DWf2 … …
#bioeurope #immunooncology #arevolutionforlife

[Alligator Bioscience @AlligatorBio]

Busy days for Alligator at @sitcancer in Washington DC. The three preclinical projects ATOR-1015, ATOR-1017 and ALG.APV-527 all to be showcased at the conference. #immunooncology #arevolutionforlife https://t.co/GT9LXQclJY

[Alligator Bioscience @AlligatorBio]

@AlligatorBio Vice President Discovery Peter Ellmark giving a talk in Copenhagen on the topic "Public Private Partnership in Immuno-Oncology" #IOCPH18 #arevolutionforlife

[Alligator Bioscience @AlligatorBio]

CEO Per Norlén now on stage @VatorSecurities Unicorn Summit @MediconVillage telling the exciting Alligator story to a high level investor audience. #immunooncology #nextgenerationctla4 #arevolutionforlife

[Alligator Bioscience @AlligatorBio]

Alligator Bioscience receives government research grant https://t.co/6U3eLHzgkM